RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Cortex Pharmaceuticals — Rodman & Renshaw 17th Annual Global Investment Conference 2015

35 slides from RespireRx Pharmaceuticals's conference presentation, Sep 8, 2015

  1. Slide 1: Cortex Pharmaceuticals, Inc. at Rodman & Renshaw Conference

    Slide 1: Cortex Pharmaceuticals, Inc. at Rodman & Renshaw Conference

    ia (XTEX PHARMACEUTICALS, INC. Cortex Pharmaceuticals, Inc. Rodman & Renshaw 17‘ Annual Global Investment Conference September 10, 2015 James S. J. Manuso, Ph.D., President & CEO

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements The matters discussed in this presentation that are not historical facts are "forward- looking statements." Forward-looking statements include, but are not limited to, statements containing the words "believes," “anticipates,” "intends," "expects," "projects" and words of

  3. Slide 3: Breath is the universal factor of life

    Slide 3: Breath is the universal factor of life

    "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." ss tan Abbot George Burke a

  4. Slide 4: The Cortex Story

    Slide 4: The Cortex Story

    The Cortex Story » Two drug platforms for breathing disorders > Four Phase 2 or Phase 2-ready programs Blockbuster markets v v IP protection with the ability to add additional IP v Multiple opportunities for strategic collaborations v Availability of non-dilutive financing > Experienced management t

  5. Slide 5: CORTEX (OTC QB:CORX): Medicines for breathing disorders

    Slide 5: CORTEX (OTC QB:CORX): Medicines for breathing disorders

    CORTEX (OTC QB:CORX): Medicines for breathing disorders The Cortex of today was created by new management, financing and the combination of two clinical-stage companies: » Pier Pharmaceuticals: a private company with rights to dronabinol, the lead, Phase 2B medicine for Sleep Apneas. » Cortex Pharma

  6. Slide 6: Cortex is a leader in the discovery and development of innovative pharmaceuticals

    Slide 6: Cortex is a leader in the discovery and development of innovative pharmaceuticals

    Cortex is a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders v Sleep Apnea ° Dronabinol for Obstructive Sleep Apnea (OSA) e Ampakines for Central Sleep Apnea (CSA) Drug-induced Respiratory Depression (RD) - Ampakines oa ° Semi-acute use —

  7. Slide 7: Advanced Product Pipeline Targeting Respiratory Disorders

    Slide 7: Advanced Product Pipeline Targeting Respiratory Disorders

    Advanced Product Pipeline Targeting Respiratory Disorde Stage of Development Compound | Indication Pre-clinical Phase 1 Phase 2 Obstructive Sleep Apnea Central Sleep Apnea Dronabinol CX1739 Opiate-induced RD Spinal Damage/Pompe Combination CX717 Formulation with Opiates for Reduced RD Drug-induced C

  8. Slide 8: Sleep Apnea: A Large Market Opportunity

    Slide 8: Sleep Apnea: A Large Market Opportunity

    Sleep Apnea: A Large Market Opportunity » Sleep Apnea ° Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep ° Three types: Obstructive, Central & Mixed » The Sleep Apnea Market is Large ° 18 million U.S. adults suffer from moderate or severe

  9. Slide 9: Obstructive Sleep Apnea (OSA)

    Slide 9: Obstructive Sleep Apnea (OSA)

    Obstructive Sleep Apnea (OSA) » Obstructive Sleep Apnea (OSA): a decrease or complete halt in airflow during sleep ° Induced by relaxation of muscles during sleep ° Soft tissue in back of throat collapses and obstructs upper airway » Significant morbidity due to stroke, hypertension, heart failure,

  10. Slide 10: CPAP Efficacy is Greatly Limited by Patient Compliance

    Slide 10: CPAP Efficacy is Greatly Limited by Patient Compliance

    CPAP Efficacy is Greatly Limited by Patient Compliance Works as an air splint to keep upper airway open during sleep 30% of diagnosed patients never initiate CPAP treatment when prescribed a machine Over 50% of patients stop using CPAP in the first year Many CPAP users wear the device for less than

  11. Slide 11: Dronabinol: a Breakthrough Treatment for OSA

    Slide 11: Dronabinol: a Breakthrough Treatment for OSA

    Dronabinol: a Breakthrough Treatment for OSA » Mechanism of Action e Dronabinol is (D-9)THC, a cannabinoid agonist » Stage of Development ° Schedule III drug available by prescription, with a low risk of addiction ° Approved for the treatment of anorexia in AIDS patients and nausea and vomiting in c

  12. Slide 12: Completed Dronabinol Phase 2A Trial in OSA

    Slide 12: Completed Dronabinol Phase 2A Trial in OSA

    Completed Dronabinol Phase 2A Trial in OSA » Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA » Placebo (N=5) or dronabinol (N=17) for 21 days ° 2.5, 5 and 10 mg/night studied with weekly dose escalation » Overnight polysomnogram (PSG) at baseline, and after

  13. Slide 13: Dronabinol Reduced the AHI in OSA Subjects

    Slide 13: Dronabinol Reduced the AHI in OSA Subjects

    Dronabinol Reduced the AHI in OSA Subjects AHI Mean % Change from Baseline to End of Treatment 40% 30% 20% P=0.17 10% Dronabinol 0% Placebo 10% P<0.01 -20% Reduction in Sleep Apnea -30% 40%

  14. Slide 14: Apnea Suppression as a Function of Dose and Time

    Slide 14: Apnea Suppression as a Function of Dose and Time

    pnea Suppression as a Function of Dose and Time C) -2 -4 -6 | -8 utst Half -12 = 2nd Half -14 -16 n=17 n= 13 n=8 AAHI versus Baseline a 3 The plasma half-life of dronabinol is 2 — 4 hours. 14

  15. Slide 15: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Slide 15: Ongoing Dronabinol Phase 2B Clinical Trial in OSA

    Ongoing Dronabinol Phase 2B Clinical Trial in OSA » 4 major centers » Potentially pivotal for an accelerated NDA » 120 subjects (40/group, 6 wks dosing) » Doses: Placebo, 2.5 mg, 10 mg qd > $5 MM NIH Grant » Completion by Q3/2016 » Initiate FDA Filing in Q4/2016 a 15

  16. Slide 16: Protecting Dronabinol in the Marketplace

    Slide 16: Protecting Dronabinol in the Marketplace

    Protecting Dronabinol in the Marketplace » Issued Method-of-Use patent for dronabinol in OSA ° Expires in 2025 » Schedule Ill drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label » Off-label use of generics and medical marijuana are not covered by

  17. Slide 17: First therapeutic available for OSA

    Slide 17: First therapeutic available for OSA

    First therapeutic available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sleep specialists to include primary care physicians and cardiologists Recurring

  18. Slide 18: Central Sleep Apnea

    Slide 18: Central Sleep Apnea

    Central Sleep Apnea » Caused by a lack of drive from the brain to breathe during sleep » Manifestations of CSA ° 70% of chronic narcotic users ° Up to 40% of heart failure patients ° 5% of sleep apnea patients have idiopathic » No therapeutic or device is approved for the indication a

  19. Slide 19: Reduce Mortality in Heart Failure Patients

    Slide 19: Reduce Mortality in Heart Failure Patients

    Reduce Mortality in Heart Failure Patients 4, Survival % i] el «| (6 AHI less than 5 per hour ii \ ee Al eur gent than S peru e " ol a a a ‘Survval of heart failure (HF) patients with or without central sleep apnea (CSA) after accounting for all ther confounders. AH = apneatypopnea index. Javaheriet

  20. Slide 20: Ampakines: Novel Treatment for Respiratory Depression

    Slide 20: Ampakines: Novel Treatment for Respiratory Depression

    AMPAKINES ovel Treatment for Respiratory Depress \ —_— PreBétzinger ~ Complex Neurons in this brainstem region control inspiratory breathing rhythm + PreBotC neurons use AMPA receptors for signaling {60S remearci consti ly Beil’ GioarUUAGeite . Opiates and other depressants mediate their Ren etal, A

  21. Slide 21: Ampakines — A Novel Class of Drugs

    Slide 21: Ampakines — A Novel Class of Drugs

    AMPAKINES — A NOVE ASS OF DRUGS AMPA Receptors Mediate Synaptic Transmission in the Brain » Glutamate is the major excitatory neurotransmitter in the CNS AMPAKINE » Fast excitatory transmission is mediated by AMPA-type glutamate receptors » Ampakines are positive, allosteric modulators of the AMPA-t

  22. Slide 22: CX1739: A Second Generation, Oral Ampakine

    Slide 22: CX1739: A Second Generation, Oral Ampakine

    CX1739: A Second Generation, Oral Ampakine in Phase 2 v Stage of Development ° Completed Phase 1 in healthy volunteers and Phase 2A in Central Sleep Apnea e IND-Ready for Phase 2 trials in opiate and propofol-induced Respiratory Depression v Targeted Indications ° Oral therapy for opiate and propofo

  23. Slide 23: CX1739: Completed Phase 2A in Central Sleep Apnea

    Slide 23: CX1739: Completed Phase 2A in Central Sleep Apnea

    CX1739: Completed Phase 2A in Central Sleep Apnea Design Randomized, double-blind, placebo-controlled study Population 20 adults with all types of moderate to severe sleep apnea (16 given CX1739; 4 given Placebo) Dosing Each subject received either placebo or a single dose of 900mg CX1739 one hour b

  24. Slide 24: Responders by Measure Group

    Slide 24: Responders by Measure Group

    Measure Group No. Responders* Apnea-Hypopnea Index CX1739 3/15 (AHI) Placebo 0/4 Apnea-Hypopnea Time CX1739 515 (AHT) Placebo 0/4 * A responder has at least a 40% decrease in the respective parameter 24

  25. Slide 25: CX1739 Was More Effective on Mixed and Central Sleep Apneas

    Slide 25: CX1739 Was More Effective on Mixed and Central Sleep Apneas

    CX1739 Was More Effective on Mixed and Central Sleep Apneas Obstructive Apneas Mixed Apneas Central Apnea g & 3S g 8 3 6. 5. Se Be ke $e SEs gis £ G 20 £o 25 ge g 3 ge & get ee ee au 2 i 2: am 4 z= 10. gu au ; ; a ; 6 0 ° = 25

  26. Slide 26: Drug-induced Respiratory Depression

    Slide 26: Drug-induced Respiratory Depression

    Drug-induced Respiratory Depression RD is the most frequent lethal side effect of opiate use Acute and Semi-Acute Use of opiates ° ~25M patients/year at risk for RD (hospitalized, peri- and post- surgical opiate patients) Chronic Opiate Use e Proprietary combination formulation for use in patients w

  27. Slide 27: Respiratory Depression in Humans

    Slide 27: Respiratory Depression in Humans

    Depression in Humans » Two clinical studies were run in normal, healthy volunteers with CX717, a first-generation Ampakine » Moderate Respiratory Depression was induced experimentally by infusion of the opioid, Alfentanil » Respiratory and analgesia end-points were measured 3 et relieving properties

  28. Slide 28: CX717 Breathing Rate in Humans

    Slide 28: CX717 Breathing Rate in Humans

    nimere O Depression in Humans CX7 NAL ‘ory Breathina Rate 16: BS (Placebo gg CX717 12: **P<0.01 NS - Not Significant Breaths/min Baseline +Alfentanil +Naloxone nil r ‘CX717 maintains respiratory rate in the presence of Alfentanil Data are expressed as the basal respiratory rate. N= 15 and 16 per gro

  29. Slide 29: CX717 Pain Sensitivity Data

    Slide 29: CX717 Pain Sensitivity Data

    [Placebo > 15 mcx717 2 = o 5 10 NS no c G & 05 0.0 Baseline +Alfentanil +Naloxone Data are expressed as the pain sensitivity, normalized to the Baseline measurement. N = 15 and 16 per group. CX717 dose is 1500mg 2

  30. Slide 30: Advanced Product Pipeline Targeting Respiratory Disorders

    Slide 30: Advanced Product Pipeline Targeting Respiratory Disorders

    Advanced Product Pipeline Targeting Respiratory Disorders Stage of Development Compound | Indication Pre-clinical Phase 1 Phase 2 Obstructive Sleep Apnea Central Sleep Apnea Dronabinol CX1739 Opiate-induced RD Spinal Damage/Pompe Combination CX717 Formulation with Opiates for Reduced RD Tl Drug-indu

  31. Slide 31: Key Objectives for the Next Months

    Slide 31: Key Objectives for the Next Months

    Key Objectives for the Next 12 Months (Pending Financing) Compound Indication Status Estimated Estimated Start Date Completion Dronabinol Obstructive Sleep Apnea Phase 2B Underway 3Q2016 Opiate-induced RD Phase 2A 4Q2015 1Q2016 CX1739 Central Sleep Apnea Phase 2A 2Q2016 3Q2016 Spinal Cord Injury, CX

  32. Slide 32: Common Stock

    Slide 32: Common Stock

    “Common Stock Common Stock Equivalents of all Convertibles Common Stock Equivalents of all Options and Warrants 413,477 112,602 144,991 671,070 34,293 215,611 250,104 447,770 112,602 360,802 921,174

  33. Slide 33: Management and Directors

    Slide 33: Management and Directors

    Management and Directors James Manuso Arnold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director CCO Agile Therapeutics Director CEO C

  34. Slide 34: The Cortex Story

    Slide 34: The Cortex Story

    The Cortex Story ¢ Two drug platforms for breathing disorders ¢ Four Phase 2 or Phase 2-ready programs * Blockbuster markets ¢ IP protection with the ability to add additional IP ¢ Multiple opportunities for strategic collaborations * Availability of non-dilutive financing « Experienced management t

  35. Slide 35: Cortex Pharmaceuticals, Inc.

    Slide 35: Cortex Pharmaceuticals, Inc.

    PHARMACEUTICALS, INC. iF (RTEX Cortex Pharmaceuticals, Inc. Rodman & Renshaw 17 Annual Global Investment Conference September 10, 2015 James S. J. Manuso, Ph.D., President & CEO

Source: SEC EDGAR · 8-K filed Sep 8, 2015

More decks from RespireRx Pharmaceuticals Inc